AbCellera Biologics Inc. Common Shares
ABCLAbCellera Biologics Inc. is a biotechnology company focused on discovering and developing monoclonal antibodies. Using its人工智能-powered platform, the company analyzes natural immune responses to identify potential therapeutic candidates for various diseases, including infectious diseases, cancer, and inflammatory conditions. Founded in 2012 and based in Canada, AbCellera collaborates with pharmaceutical and biotech partners to advance its antibody discovery pipeline.
Company News
Prelude Therapeutics reported a Q2 2025 net loss of $31.2 million, reduced operating expenses, and focused on its oral SMARCA2 degrader program while maintaining cash reserves to fund operations into Q2 2026.
The antibody discovery market is projected to grow at a 10% CAGR by 2032, driven by increasing chronic disease incidence, biologics adoption, and technological advancements in drug development.
Wall Street analysts say this drug developer can more than double your money.
ABCL earnings call for the period ending March 31, 2024.
AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 12.50% and 11.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
